Pfizer R&D in China: Building a Virtual R&D Network, Part 2
This article was originally published in PharmAsia News
Executive Summary
While many multinational companies have taken a brick-and-mortar approach to R&D in emerging markets, Pfizer is betting that a virtual network will give it the flexibility and access to talent it needs to succeed in China. Pfizer's president of global R&D, Martin Mackay, and Stephen Yang, who heads Pfizer's Asia R&D efforts, outline that strategy in a two-part interview. Two of the most important figures in Pfizer's worldwide research endeavors, Mackay and Yang were interviewed by Elsevier writers Ellen Licking and Wendy Diller. This is part two of the interview; part one apeared in a recent issue of PharmAsia News.
You may also be interested in...
Pfizer Head of Preclinical Outsourcing VP Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 1 of 2)
On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.
Pfizer’s Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships
On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.
Pfizer Returns To Japan To Identify Technology And Compound Targets
TOKYO - Two years after closing a research lab in Japan, Pfizer is looking to rebuild a focus on Japanese innovation and technology